Literature DB >> 9279566

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas.

T Tomita1.   

Abstract

AIMS: Hyperplastic C-cells of the thyroid and medullary thyroid carcinomas (MTCs) were studied immunocytochemically for calcitonin, carcinoembryonic antigen (CEA), chromogranin A, matrix metalloproteinase (MMP)-2 and -9, and tissue inhibitor of metalloproteinase (TIMP)-1 and -2. METHODS AND
RESULTS: Non-neoplastic C-cells were positive for all these substances whereas MTC tumour cells were relatively weaker stained, and thyroid follicular cells were negative for all the substances studied. We have recently reported that pancreatic islet cells and islet cell tumours were positive for MMPs and TIMPs, and, in addition, anterior pituitary cells and pituitary adenomas and parathyroid gland and its adenomas were also positively stained. The MMP- and TIMP-positive endocrine cells correspond to Pearse's APUD cells, derived from neural crest and endodermal cells.
CONCLUSIONS: MMPs and TIMPs may well be added as newly recognized markers for neuroendocrine cells. The possible function of MMP-TIMP homeostasis in C-cells and MTCs is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279566     DOI: 10.1046/j.1365-2559.1997.2160834.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

Review 2.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma.

Authors:  Héctor Vázquez-Lorente; Duško M Dundjerović; Svetislav B Tatić; Sara Rodríguez-Menéndez; Héctor González-Iglesias; Cláudio M Gomes; Ivan R Paunović; Vesna V Dragutinović
Journal:  Biol Trace Elem Res       Date:  2022-09-26       Impact factor: 4.081

4.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.

Authors:  Charlotte Aaberg-Jessen; Karina Christensen; Hanne Offenberg; Annette Bartels; Tanja Dreehsen; Steinbjørn Hansen; Henrik Daa Schrøder; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Immunocytochemical Localization of Prohormone Convertase 1/3 and 2 in Thyroid C-Cells and Medullary Thyroid Carcinomas.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

6.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Pituitary Adenomas: Possible Markers of Neuroendocrine Cells.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

7.  Reduced tissue inhibitor of metalloproteinase-2 expression is associated with advanced medullary thyroid carcinoma.

Authors:  Simone Magagnin Wajner; Clarissa Capp; Beatriz Assis Brasil; Luise Meurer; Ana Luiza Maia
Journal:  Oncol Lett       Date:  2013-12-19       Impact factor: 2.967

Review 8.  Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials.

Authors:  Hong-Yan Liu; Wei-Jun Gu; Cheng-Zhi Wang; Xiao-Jian Ji; Yi-Ming Mu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma.

Authors:  Tatsuo Tomita
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.